The World Health Organization now estimates that up to 45% of dementia cases trace back to factors people can change, not ones they're born with. That number comes from WHO's second-edition guidelines on reducing cognitive decline and dementia risk, published 15 July 2026, which name hypertension, diabetes, obesity, inactivity, smoking, heavy alcohol use, social isolation, air pollution, and untreated hearing or vision loss as the modifiable targets. The harder question for a midlife adult is not whether the estimate is real, but whether the systems meant to act on it are available to them. Across hypertension, diabetes, and hearing care, large majorities of people with a treatable condition are not getting treated for it, and the guidance itself is landing in countries with little dedicated capacity to deliver on it.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Where the 45% figure comes from, and what it actually measures
- Which risk factors apply specifically in midlife
- The access gap on the two most common midlife targets
- Why hearing loss is treated and ignored at the same time
- Why people don't act even when care is reachable
- How WHO's 2026 guidance tries to close the gap
- Frequently Asked Questions
Where the 45% figure comes from, and what it actually measures
The 45% is not a measured drop in dementia cases from any completed program. It is a population-attributable-fraction estimate: a calculation of how much dementia risk would theoretically disappear if every modifiable factor were fully eliminated across the population. The figure traces to the 2024 Lancet Commission report, which expanded an earlier list of 12 risk factors to 14 by adding high LDL cholesterol in midlife and untreated vision loss in later life. The calculation assumes each factor is causal and that it could, in principle, be removed entirely. WHO's guidelines, which replace the agency's 2019 edition, adopt that estimate and translate it into practice recommendations.
WHO and the Pan American Health Organization frame the stakes this way: more than 57 million people live with dementia worldwide, over 60% of them in low- and middle-income countries, with nearly 10 million new diagnoses added every year. That framing matters for how a reader should read the number. It is a ceiling on what's theoretically possible, not a forecast of what current health systems will deliver. As Psychology Today notes, WHO itself flags evidence gaps in several of the risk-factor areas the estimate rests on. The gap between the theoretical 45% and what actually gets prevented depends entirely on access to treatment and follow-through on it — which is where midlife adults run into trouble.
Which risk factors apply specifically in midlife
The Lancet Commission splits its 14 factors by life stage, and midlife carries a distinct set. For adults roughly in their 40s and 50s, the modifiable targets are hearing loss, high LDL cholesterol, depression, traumatic brain injury, physical inactivity, diabetes, smoking, hypertension, obesity, and excessive alcohol use, according to reporting on the Commission's findings. Later-life factors — social isolation, air pollution exposure, and untreated vision loss — are tracked separately.
The distinction is practical, not academic. A 45-year-old managing blood pressure and cholesterol is addressing a different set of risks than a 75-year-old dealing with isolation or vision decline. Midlife intervention also has more runway: the conditions on this list are generally ones that compound over years before symptoms of cognitive decline would appear. That gives a midlife adult a longer window to act, but it also means the barriers below — cost, access, and awareness — have more years to do damage if they go unaddressed.
The access gap on the two most common midlife targets
Hypertension and diabetes are the two conditions on the midlife list affecting the largest number of people, and both show the same pattern: the condition is common, but treatment is not. WHO's Global Hypertension Report found roughly 1.4 billion people had hypertension in 2024, but only about one in five had it under control, and nearly half of surveyed countries reported national control rates below 20%. Diabetes shows a similar shortfall.
Among roughly 828 million adults worldwide with diabetes, 59% of those aged 30 and older — about 445 million people — were receiving no treatment at all, according to an NCD-RisC and WHO analysis published in The Lancet. That treatment gap is heavily concentrated in low- and middle-income countries — the same regions carrying over 60% of the world's dementia cases. For a midlife adult, this means the two largest items on the modifiable-risk list are, for hundreds of millions of people, not actually being modified. A diagnosis exists, but the medication, monitoring, or follow-up care that would change the trajectory often doesn't reach them.
Why hearing loss is treated and ignored at the same time
Hearing loss sits first on the midlife list, but it illustrates a different kind of barrier: cost and stigma rather than diagnosis. Hearing aid uptake among adults with hearing loss runs roughly 20% to 40% in the United States, held down by device prices around $4,700 per pair without insurance, according to a CIICA research brief.
The same brief found that hearing aid ownership among low-income older adults actually fell between 2011 and 2018, even as ownership rose among the wealthiest adults over the same period. That divergence is a warning sign for a risk factor on WHO's list: a treatable condition where the people least able to pay are losing ground, not gaining it, while the condition itself carries a documented dementia-risk association significant enough to make the Commission's top-10 midlife list.
Why people don't act even when care is reachable
Even where treatment is accessible, awareness is a separate barrier. A qualitative study from the In-MINDD project, conducted across four European countries, found low understanding of modifiable dementia risk among both midlife adults and the primary-care professionals treating them, according to the Society for Academic Primary Care.
Many participants in the study believed genetic risk could not be changed through lifestyle action at all — a belief that undercuts the entire premise of the 45% estimate before a prescription or referral ever enters the picture. This matters because it means the barrier isn't only supply-side. A midlife adult with insurance, a nearby clinic, and a treatable blood pressure reading can still not act on it if neither they nor their primary-care provider frames hypertension as a dementia-relevant condition rather than purely a cardiovascular one.
How WHO's 2026 guidance tries to close the gap
Rather than propose new, standalone dementia-prevention programs, WHO's 2026 guidance directs countries to fold dementia risk reduction into the noncommunicable-disease, mental-health, and brain-health services that already exist, per WHO's published guidelines. The logic follows directly from where most affected people live: countries with scarce dedicated dementia or cognitive-screening infrastructure, where a new specialty track would likely go unused. For a midlife adult, this translates into a practical takeaway: the same hypertension visit, diabetes check, or hearing evaluation already on the calendar is the point of contact WHO expects to carry the dementia-risk conversation — not a separate dementia-specific appointment that, for most of the world, doesn't exist.
- Blood pressure and blood glucose checks already on a routine physical cover two of the three largest midlife targets.
- A hearing evaluation is worth requesting explicitly; it's rarely volunteered during a general checkup.
- Asking a primary-care provider directly whether a given condition is "on the dementia risk list" addresses the awareness gap the In-MINDD study identified — many providers don't raise it unprompted.
Frequently Asked Questions
Is the 45% figure a guarantee that dementia can be prevented?
No. It's a theoretical ceiling assuming every modifiable risk factor is fully eliminated across a population, not a measured result from any completed prevention program, per Psychology Today's coverage of the estimate's limits.
Which risk factor on the list is most specific to midlife rather than older age?
High LDL cholesterol in midlife is one of the two factors the 2024 Lancet Commission added to the original list, specifically tied to that life stage, according to the Commission's findings.
Does having hypertension or diabetes automatically mean someone is being treated for it?
No. Global data show roughly 80% of people with hypertension lack controlled blood pressure, and 59% of adults 30 and older with diabetes receive no treatment at all, per WHO's Global Hypertension Report and the NCD-RisC/Lancet diabetes analysis.
You Might Also Like
- Cross-Cultural Dementia Risk Programs After LatAm-FINGERS 2026: Access and Adherence Barriers for Adults in Midlife
- WHO’s Second Dementia Risk-Reduction Guideline in 2026: Access and Adherence Barriers for Adults in Midlife
- UAS-CLEAR Dementia Care Research Data Priorities in 2026: Why the Findings May Not Change Care Yet for Adults With Memory Concerns
